Logo

Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products

Share this
Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products

Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products

Shots:

  • Encore through its subsidiary Promius Pharma- has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate)- Trianex (Triamcinolone Acetonide Ointment- USP) and Promiseb from Dr. Reddy
  • The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis- atopic dermatitis and acne
  • Sernivo (betamethasone dipropionate) spray 0.05% is targeted to reduce the symptoms of mild-to-moderate plaque psoriasis- such as itching- flaking & redness. Trianex 0.005% is a corticosteroid ointment used to relief inflammatory and itching symptoms of corticosteroid-responsive skin diseases

Ref: Business Wire | Image: Twitter

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions